Cargando…

Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study

INTRODUCTION: Dual diethylcarbamazine and albendazole (DA) therapy is the standard mass drug administration (MDA) regimen for lymphatic filariasis in Kenya. Following the recent World Health Organization recommendation, Kenya piloted triple therapy with ivermectin, diethylcarbamazine, and albendazol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khaemba, Christabel, Barry, Abbie, Omondi, Wyckliff P., Kirui, Elvis, Oluka, Margaret, Parthasarathi, Gurumurthy, Njenga, Sammy M., Guantai, Anastacia, Aklillu, Eleni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584738/ https://www.ncbi.nlm.nih.gov/pubmed/37552438 http://dx.doi.org/10.1007/s40264-023-01338-9

Ejemplares similares

Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study
por: Khaemba, Christabel, et al.
Publicado: (2021)

Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa—Ethiopia, Kenya, Rwanda, and Tanzania
por: Barry, Abbie, et al.
Publicado: (2021)

The Role of Personal Opinions and Experiences in Compliance with Mass Drug Administration for Lymphatic Filariasis Elimination in Kenya
por: Njomo, Doris W., et al.
Publicado: (2012)

Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach
por: Njomo, Doris W., et al.
Publicado: (2020)

Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya
por: Njomo, Doris W., et al.
Publicado: (2020)

Towards elimination of Lymphatic Filariasis in Kenya: improving advocacy, communication and social mobilization activities for mass drug administration, a qualitative study
por: Kibe, Lydiah W., et al.
Publicado: (2022)

Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa
por: Fischer, Peter U., et al.
Publicado: (2017)

Elimination of Lymphatic Filariasis in The Gambia
por: Rebollo, Maria P., et al.
Publicado: (2015)

Safety and Tolerability of Ivermectin and Albendazole Mass Drug Administration in Lymphatic Filariasis Endemic Communities of Tanzania: A Cohort Event Monitoring Study
por: Fimbo, Adam M., et al.
Publicado: (2022)

Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania
por: Barry, Abbie, et al.
Publicado: (2020)

The history of the elimination of lymphatic filariasis in China
por: De-jian, Sun, et al.
Publicado: (2013)

Evaluating the Evidence for Lymphatic Filariasis Elimination
por: Davis, Emma L., et al.
Publicado: (2019)

Pacific collaboration to eliminate lymphatic filariasis
por: Ichimori, Kazuyo, et al.
Publicado: (2005)

Diagnostics to support elimination of lymphatic filariasis—Development of two target product profiles
por: Won, Kimberly Y., et al.
Publicado: (2021)

Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania
por: Fimbo, Adam M., et al.
Publicado: (2020)

Progress on elimination of lymphatic filariasis in Sierra Leone
por: Koroma, Joseph B., et al.
Publicado: (2018)

Elimination of lymphatic filariasis in South East Asia
por: Specht, Sabine, et al.
Publicado: (2019)

An investigation of the disparity in estimates of microfilaraemia and antigenaemia in lymphatic filariasis surveys
por: Cano, Jorge, et al.
Publicado: (2015)

Defining the cost of the Egyptian lymphatic filariasis elimination programme
por: Ramzy, Reda MR, et al.
Publicado: (2005)

Lymphatic filariasis in Brazil: epidemiological situation and outlook for elimination
por: Fontes, Gilberto, et al.
Publicado: (2012)

Population Migration: Implications for Lymphatic Filariasis Elimination Programmes
por: Ramaiah, K. D.
Publicado: (2013)

Achievements and challenges of lymphatic filariasis elimination in Sierra Leone
por: Bah, Yakuba M., et al.
Publicado: (2020)

Progress towards elimination of lymphatic filariasis in the Americas region
por: Fontes, Gilberto, et al.
Publicado: (2020)

Caring for patients in the global programme to eliminate lymphatic filariasis
por: Mackenzie, Charles D, et al.
Publicado: (2020)

Modelling strategies to break transmission of lymphatic filariasis - aggregation, adherence and vector competence greatly alter elimination
por: Irvine, M. A., et al.
Publicado: (2015)

Impact of the Lymphatic Filariasis Control Program towards elimination of filariasis in Vanuatu, 1997–2006
por: Allen, Tammy, et al.
Publicado: (2017)

Lessons from lymphatic filariasis elimination and the challenges of post-elimination surveillance in China
por: Fang, Yuan, et al.
Publicado: (2019)

National Mass Drug Administration Costs for Lymphatic Filariasis Elimination
por: Goldman, Ann S., et al.
Publicado: (2007)

Global Elimination of Lymphatic Filariasis: Addressing the Public Health Problem
por: Addiss, David G.
Publicado: (2010)

Global Elimination of Lymphatic Filariasis: A “Mass Uprising of Compassion”
por: Addiss, David G.
Publicado: (2013)

Translating Research into Reality: Elimination of Lymphatic Filariasis from Haiti
por: Lammie, Patrick J., et al.
Publicado: (2017)

Overview of PacELF—the Pacific Programme for the Elimination of Lymphatic Filariasis
por: Ichimori, Kazuyo, et al.
Publicado: (2017)

Elimination of lymphatic filariasis: current perspectives on mass drug administration
por: Gyapong, John O, et al.
Publicado: (2018)

Impact of mass drug administration for elimination of lymphatic filariasis in Nepal
por: Ojha, Chet Raj, et al.
Publicado: (2017)

Lymphatic filariasis in Fiji: progress towards elimination, 1997–2007
por: Manolas, Rosie K., et al.
Publicado: (2020)

Elimination of Lymphatic Filariasis in Shandong Province, China, 1957–2015
por: Huang, Xiaodan, et al.
Publicado: (2020)

The role of medicine donations in the global programme for the elimination of lymphatic filariasis
por: Williams, Tijana, et al.
Publicado: (2020)

Progress towards elimination of lymphatic filariasis in the Eastern Mediterranean Region
por: Ramzy, Reda M R, et al.
Publicado: (2020)

Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis
por: Turner, Hugo C
Publicado: (2020)

Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India
por: Sabesan, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8e657hluhp46guv7lbsi4k4ghm